Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism

Neurochem Res. 2019 Jan;44(1):102-116. doi: 10.1007/s11064-018-2521-z. Epub 2018 Apr 3.

Abstract

In the past couple of decades, major efforts were made to increase reliability of metabolic assessments by magnetic resonance methods. Magnetic resonance spectroscopy (MRS) has been valuable for providing in vivo evidence and investigating biomarkers in neuropsychiatric disorders, namely schizophrenia. Alterations of glutamate and glutamine levels in brains of schizophrenia patients relative to healthy subjects are generally interpreted as markers of glutamatergic dysfunction. However, only a small fraction of MRS-detectable glutamate is involved in neurotransmission. Here we review and discuss brain metabolic processes that involve glutamate and that are likely to be implicated in neuropsychiatric disorders.

Keywords: Glutamate; Glutamine; Magnetic resonance; Metabolism; Schizophrenia.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Energy Metabolism / physiology*
  • Glutamic Acid / metabolism*
  • Humans
  • Magnetic Resonance Spectroscopy / methods*
  • Schizophrenia / diagnostic imaging
  • Schizophrenia / metabolism*

Substances

  • Glutamic Acid